{"name":"Veloxis Pharmaceuticals","slug":"veloxis-pharmaceuticals","ticker":"","exchange":"","domain":"veloxis.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOLUpWaUt1dERhR2FqVFVoV3h0V0JpaVBjYjRQbk1rVk1ZdThJOXc4bHFvclh5UjBHN1c2Q1hfaVYtUDNnd0hkME9EemZhaGxJR0EtMU9qWTJycjVPaHM2V0dfZHFQZ1M1aEcwNy1HdFQxcTRiZ1NEZVpaREg3a01FaFpFMXlfTXV4a3pSTFhHMHlHcGNxU0xsOVRYY1ZMR0hnVjRoRUJPN1hPZ0oxaHp2NE5ESVlmQQ?oc=5","date":"2026-04-07","type":"deal","source":"Bloomberg Law News","summary":"Veloxis’ Deal With Sun Blocks Envarsus XR Generic Before 2028 - Bloomberg Law News","headline":"Veloxis’ Deal With Sun Blocks Envarsus XR Generic Before 2028","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE9STFRSamlodEdQcmpOMGJxaEpKM3NsODc2TjA0R1BqNjBxTmZ5NFFOOUJsZEdnTExlVFBDbG5xTUxGOUZJT0tNUmNaaUZCR3dWQnpB?oc=5","date":"2026-02-26","type":"trial","source":"FirstWord Pharma","summary":"Biopharma bites: Asahi Kasei buys antiviral spinout, Protagonist's payout, layoffs at Viatris, plus AtaiBeckley's anxiety data - FirstWord Pharma","headline":"Biopharma bites: Asahi Kasei buys antiviral spinout, Protagonist's payout, layoffs at Viatris, plus AtaiBeckley's anxiet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxORjJYb1M5RlIyYjFMRGZDcmRCbXBodlotVnREcmNZYzFhMEdRTUVibXNUM2NTaERnc2lFaWduNnNSeHJ4anM5QXdKTzU0RWVKWnY5V0ZHUklGVFh5NDV3ZDRYWVJCVzZXNVpxX0hMdTFOQ0x6eEh1dE5sMHVLVmdUR003anJ4U0xxVWR5ckRISlk2RmZraVlzLWp0RERQR3FWVUZEeQ?oc=5","date":"2026-02-26","type":"pipeline","source":"Fierce Biotech","summary":"Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost - Fierce Biotech","headline":"Asahi Kasei scoops up Germany's Aicuris for $920M in R&D portfolio boost","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQVFJPSjJLSjRGUFVpTWlpenVCS0tJV0wzVlhfNldDQlg0enNJTDA3WUN2cFUyQTgzamFRbmdiOFltVl9QZnhWNW5KWnoxdTJTejY4UkQtekYteExaMHlqcWptM1NjNlQ0dkFSU0pTYWRLc29kV2xoMngtWFBJVkhENDJJZnlKRVJ3WWl0OGx3OU9haHNKTGV1WW0zY002UQ?oc=5","date":"2026-02-26","type":"deal","source":"The Pharma Letter","summary":"Aicuris to be acquired by Asahi Kasei for $920 million - The Pharma Letter","headline":"Aicuris to be acquired by Asahi Kasei for $920 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxQaVVUYU0wZkpJVncwMHNTNmFiRVJvRmdkdU1qRG1uWUJsZGZ1T21RZEF1ekUwVmF1UGpGQVhvdHB5OWR3aC02RHZwcGFnVU8wZVU3SEpFYXM4U0Utdk4zczJ3NVRudHR0Y0ZVb3pEMzBVNjVwOE1ZUDdSZnhoZExaZjRrZXJ4OWJJQVRHTE1takVES3JJdy1WUjZUQW5sZW5LSGRQdzZ2OW1qc0lVMmM1VkhJVXdSQjBoNzMzT09ybF9iRmg4MEVlRmhnanYySzlRcmtnLVhhT0duNG9odktYbWhlX2l6TzE0bjJ1SWtWT1Y4a0JxV1RfUXlLOUNSWmFOQ3RGWFZ5cGI4UHFESlQtN0gtVG1tTkF6TkRZ?oc=5","date":"2026-02-18","type":"trial","source":"Business Wire","summary":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refractory Diseases - Business Wire","headline":"Asahi Kasei Pharma and Alchemedicine Advance a Novel Therapeutic Candidate Into Phase I Study for the Treatment of Refra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFAyblpQVWRHazBDemtteGJDbW1aM2hnUTdyQUdvamNKQklIRWVmb2hiQWdnOXFvRXVPYXVGMVNfQlNlM2UwRlpfQWtuTzRvRTFHd2tPYmhVSGJKSkxpc0RjOUJzX2pNZHVfTkQxYkFoUGlCdkMzZ1Q4NWN5Mkc3YnM?oc=5","date":"2025-06-10","type":"pipeline","source":"Medical Marketing and Media","summary":"Agency 100 2025: Silverlight Digital - Medical Marketing and Media","headline":"Agency 100 2025: Silverlight Digital","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOUXZySjZGOFktOGV4bjhVNVdCakR0UERnajVhYUhUYVVKaWtpYUtTc0hoZEhzQ0dlQU8yZ3h2YkdXcEtHRmFPMmlfS0swLWdfOWYyUUxndkw3c3NPNjJZM0FiNVpMZ0kzRV9za1Foa1Nvdlh4alNYVFdweHJXcUhqeHlJUl9NTVBKOVN1NGtndGdJTlpwdmc?oc=5","date":"2024-05-28","type":"pipeline","source":"BioSpace","summary":"Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics - BioSpace","headline":"Asahi Kasei Offers $1.1B for Swedish Pharma Calliditas Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRk9SQ3RBVjBIQmVTUDZxY0RLQUFyYVNDdmxWLU1BMEY5VXktcUExc09FVTZ2SnUzR043VHhwdDF6OEphM2xwdGlFbm10M1g5MzJmSlhJTkxLTW5NLXJiU0tCdGJVcFBEMURKZTJlcF9rY3JVQjBGS1JrRG4wMGNROGNNLVczbHNqdVNfOXd5RXBMQQ?oc=5","date":"2024-05-28","type":"deal","source":"Fierce Pharma","summary":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas - Fierce Pharma","headline":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPYVRqUXdyWTBhVHRzNnlDdzZVYXRVelBHeU5fM3Zsc0JaLUx5ZHFkNlQwblVzam9BNU8zVlR1MndHM0NUMEV5dVg3NEFkZVlEb1lCcHlNT2Etb3NFMDFyemF0aHJENzRhVWpxeG9IVlNzMmRyWkdqeHlLbW9EYWZCTHlfQUdZVHFPbHhLRk5oc2pQWkE2RUtpQTJSVVdPZDBDbzB5SzMxZ2NtdXM?oc=5","date":"2022-02-22","type":"pipeline","source":"The Business Journals","summary":"Growing Cary pharma earns key designation to advance transplant drug - The Business Journals","headline":"Growing Cary pharma earns key designation to advance transplant drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQVktVOVQyUkNEcENEMUhFZ2NicGNZTTZuN203eElxYmZrb1BBUHdqYXNVVnA0dU9BcmNwNC16RUxVUXEwNi1IOWdsY3UxenRrel83UlllRzd1dnhUMjExbXBuMDdTSG9BVEVOWFVQckNsaVlmanBjb1kwYmxPMmM4STR3VnlfX2haaTdfNmRDbUcwNXctTHNTQm9vQktKV1hKY0hKX2hRUG5rVTRIWE11TTFFeFVoazY5M0VVZTlVY2JrSzlDN0lPRVFZRXk0UzE4LTdsMEJTVm9oSGtIc0M5ZW4xZ0FhZ1JYTWQwbFZkMGs3Q2Fpam1zemtQN2YtdndCTDJhZ3NxLVkwdWEtU3Y3XzFLc3dzOFc3bzE4ZS1vcGdGRTAxUG8yQk5oRDFFeG5tYU5TSGFlQV9fUWV1RmlTbEhaMEZSRDc5RDNyNXFlVHVpeUJCdEx6OE93cEVZX3N5?oc=5","date":"2021-04-26","type":"deal","source":"PR Newswire","summary":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market - PR New","headline":"OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Comm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNZlVwNzZlSU13WWxRd2xJR3gwSGdxaXVKM3I1YmZ4WEliY3Y2Q2IxS1lEU0FJR1JRdnNUa0lmaFFDazdsS3dsSEgxc0hrT3k5QmRDYWxCT004SVZpZzl6NktOZnlNZThybnNZbzB2cEd0cjc0NzIzM0ZZczI1QktQYw?oc=5","date":"2020-03-22","type":"pipeline","source":"C&EN","summary":"Why Japan’s chemical firms still make drugs - C&EN","headline":"Why Japan’s chemical firms still make drugs - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVHhndGZsUmNsRUFsamhBQzVvXzBWSmNqVE96b0ZQLVNzSUNLbVRsSEU1eXhxczZNUWZZd1R1c0U4cU9oOUY0V1NZLTZsYzRSYUZTdk9NN2pLT2hSSUNtdXZTNlg1TDNGbFhBNWktSnNwZFF5Si12NjVseU1jM0FWRWVScm1wNkZJTDFn?oc=5","date":"2019-11-26","type":"deal","source":"Pharmaceutical Technology","summary":"Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn - Pharmaceutical Technology","headline":"Asahi Kasei offers to buy Veloxis Pharmaceuticals for $1.3bn","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}